Bringing the fundamentals into focus…
Back to The Oncology Institute, Inc.
How The Oncology Institute, Inc. stacks up
STLN · against 1,336 other Healthcare companies
Valuation
75/ 100
Above the middle of the pack.
Ranked #329 of 1,337 · scores higher than 75% of peers
Bars: peers in each 10-point band of the valuation score134 peers with a valuation score of 70–79, including STLN · Click a bar to see the companies
Why valuation scores 75?
Weighted metrics compared with all Healthcare companies.Its metrics sit close to the Healthcare norm.
- Negative (a loss or cash outflow), so it counts as zero whatever the share price. EBITDA yield: -2.8% vs peer median 4.0%
- lower earnings for the price paid: weaker than 72% of peers. Earnings yield: 9383.3% vs peer median 1.5%
- Negative (a loss or cash outflow), so it counts as zero whatever the share price. Free cash flow yield: -0.5% vs peer median 0.0%
Metric by metric
Position: dot = STLN, ranked from the worst peer (left) to the best (right); tick = middle, shaded = middle half of peers.| Metric | STLN | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 1,287 reported | -4.6% | 1.5% | 28% | 30% | |
| EBITDA yieldHigher is better · 1,357 reported | -2.7% | 4.2% | 25% | 50% | |
| Free cash flow yieldHigher is better · 711 reported | -0.5% | -1.0% | 51% | 20% | |
| Book yieldHigher is better · 1,306 reported | -3.9% | 37.9% | 4% | Context only |
Ranking by valuation score
Top 5 and the companies ranked around STLNScores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score